Aurobindo gets USFDA nod to market generic Osteoporosis drug
New Delhi: Aurobindo Pharma today said it has received final approval from USFDA to manufacture and market generic version of Risedronate Sodium tablets, used in the treatment of Osteoporosis, in the American market.The company has received final approval from US Food & Drug Administration (USFDA) to manufacture and market Risedronate Sodium tablets, Aurobindo Pharma said in a...
Login or Register to read the full article
New Delhi: Aurobindo Pharma today said it has received final approval from USFDA to manufacture and market generic version of Risedronate Sodium tablets, used in the treatment of Osteoporosis, in the American market.
The company has received final approval from US Food & Drug Administration (USFDA) to manufacture and market Risedronate Sodium tablets, Aurobindo Pharma said in a statement.
The approval is an extension of tentative nod received by the company on October 10, 2012, it added.
"This product is ready for launch," the company added.
Aurobindo's product is therapeutically equivalent to Warner Chilcott Co's Actonel tablets, which is used in the treatment of Osteoporosis.
The approved product has an estimated market size of USD 113 million for the twelve months ending October 2015, according to IMS data.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd